Merck Starts Phase 1 Trial of Oral Peptide Developed With Cyprumed's Technology

MT newswire2026/09/29 10:56

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

06:56 AM EDT, 09/29/2026 (MT Newswires) -- Merck (MRK) has initiated a phase 1 clinical trial of an oral peptide drug candidate that was formulated using Cyprumed's oral tablet technology, Cyprumed said Tuesday. The trial is covered under the companies' April 2025 non-exclusive license and option deal that allows Merck to develop oral peptide formulations using Cyprumed's drug delivery technology, according to the statement. Cyprumed said the deal entitles it to upfront and milestone payments of up to $493 million. No other trial details were disclosed. Cyprumed said the trial triggers a payment under the agreement with Merck, without disclosing the specific amount.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Broadcom is leading a $60 billion debt financing initiative to provide funding for AI companies such as Anthropic to purchase chips and build data centers. Of this amount, $42 billion in senior secured bonds will be syndicated by Broadcom with Wall Street banks, while $18 billion in subordinated debt is being led by Blackstone, whose funds have committed $9 billion. The deal has been in preparation for several weeks but has not yet been officially announced.

华尔街见闻•2026/10/02 10:16

Lloyds and Visa Tested Cross-Border Stablecoin Settlement Between the U.K. and the U.S.

Coinspaidmedia•2026/10/02 10:15

Euro trims daily gains as Eurozone inflation accelerates above expectations

FXStreet•2026/10/02 10:09